{"title":"Quality control frequency: Unleashing the truth.","authors":"Hikmet Can Çubukçu","doi":"10.1016/j.cca.2024.120068","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study investigates the optimal number of quality control (QC) events per day in two scenarios: high-sensitive troponin, requiring three levels of QC materials, and creatinine, with two levels. The aim is to explore how different QC rules and sigma metric values affect the frequency of QC events, considering both analytical performance and the clinical impact of potential measurement errors as severity of harm.</p><p><strong>Methods: </strong>Risk-based QC calculations were performed using the QC Constellation tool. Four QC rule schemes (1-3 s, 1-3 s/2-2 s, 1-3 s/2-2 s/R-4 s, 1-3 s/2-2 s/R-4 s/4-1 s) were tested for high-sensitive troponin (catastrophic harm) and creatinine (serious harm). Sigma metric values from 3 to 6 were evaluated to determine maximum run sizes. QC event frequency was estimated for a hypothetical laboratory processing 1,000 samples daily.</p><p><strong>Results: </strong>Maximum run sizes decreased as sigma metric values declined. Correspondingly, the number of QC events per day increased as sigma metric values decreased. For high-sensitive troponin, with its catastrophic severity of harm related to potantial error, more frequent QC was necessary compared to creatinine.</p><p><strong>Conclusions: </strong>Analytical performance and severity of harm significantly influence the required frequency of QC events. Laboratories must consider both factors when designing QC strategies to balance patient safety with operational efficiency. For analytes with high severity of harm, achieving higher sigma metrics is critical to maintain feasible and cost-effective QC practices. A hybrid QC approach combining risk-based and patient-based methods may optimize QC strategies, but standardization of sigma metric calculations is still needed.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120068"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2024.120068","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study investigates the optimal number of quality control (QC) events per day in two scenarios: high-sensitive troponin, requiring three levels of QC materials, and creatinine, with two levels. The aim is to explore how different QC rules and sigma metric values affect the frequency of QC events, considering both analytical performance and the clinical impact of potential measurement errors as severity of harm.
Methods: Risk-based QC calculations were performed using the QC Constellation tool. Four QC rule schemes (1-3 s, 1-3 s/2-2 s, 1-3 s/2-2 s/R-4 s, 1-3 s/2-2 s/R-4 s/4-1 s) were tested for high-sensitive troponin (catastrophic harm) and creatinine (serious harm). Sigma metric values from 3 to 6 were evaluated to determine maximum run sizes. QC event frequency was estimated for a hypothetical laboratory processing 1,000 samples daily.
Results: Maximum run sizes decreased as sigma metric values declined. Correspondingly, the number of QC events per day increased as sigma metric values decreased. For high-sensitive troponin, with its catastrophic severity of harm related to potantial error, more frequent QC was necessary compared to creatinine.
Conclusions: Analytical performance and severity of harm significantly influence the required frequency of QC events. Laboratories must consider both factors when designing QC strategies to balance patient safety with operational efficiency. For analytes with high severity of harm, achieving higher sigma metrics is critical to maintain feasible and cost-effective QC practices. A hybrid QC approach combining risk-based and patient-based methods may optimize QC strategies, but standardization of sigma metric calculations is still needed.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.